Hisato Takagi1, Yosuke Hari2, Norikazu Kawai3, Toshiki Kuno4, Tomo Ando5. 1. Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan; Department of Cardiovascular Surgery, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: kfgth973@ybb.ne.jp. 2. Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan; Department of Cardiovascular Surgery, Kitasato University School of Medicine, Sagamihara, Japan. 3. Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. 4. Department of Medicine, Mount Sinai Beth Israel Medical Center, New York, NY, USA. 5. Department of Cardiology, Detroit Medical Center, Detroit, MI, USA.
Abstract
BACKGROUND: We performed meta-analysis and meta-regression of transcatheter aortic valve implantation (TAVI) for the bicuspid aortic valve (B-AV) versus the tricuspid aortic valve (T-AV). METHODS: MEDLINE and EMBASE were searched through June 2018 using PubMed and OVID. We included comparative studies of TAVI patients with B-AV versus T-AV reporting at least one of postprocedural transcatheter valve regurgitation (TVR)/pacemaker implantation (PMI) incidence and early (30-day or in-hospital)/late (including early) mortality. For each study, crude (unadjusted) data regarding TVR/PMI incidence and early/late mortality in both the B-AV and T-AV groups were used to generate risk ratios (RRs). Study-specific estimates were combined in the random-effects model. Using meta-regression, we assessed potential confounders identified in preliminary meta-analysis. RESULTS: We identified 12 eligible studies including a total of 1045 B-AV and 4069 T-AV patients. Pooled analysis demonstrated an association of B-AV with a statistically significant increase in TVR incidence (RR, 1.42; p=0.006) but no statistically significant difference in PMI incidence (p=0.54) and 30-day (p=0.11)/midterm (1-year to 2-year) mortality (p=0.99) between patients with B-AV and those with T-AV. All meta-regression coefficients of 6 identified potential confounders (age, mean aortic valve gradient, aortic valve area, left ventricular ejection fraction, aortic calcification, and B-AV types) for the outcomes (TVR/PMI incidence and early/late mortality) were statistically non-significant. CONCLUSIONS: Postprocedural PMI incidence and 30-day/midterm (1-year to 2-year) mortality after TAVI may be similar between patients with B-AV and those with T-AV despite the significant association of B-AV with increased postprocedural TVR incidence.
BACKGROUND: We performed meta-analysis and meta-regression of transcatheter aortic valve implantation (TAVI) for the bicuspid aortic valve (B-AV) versus the tricuspid aortic valve (T-AV). METHODS: MEDLINE and EMBASE were searched through June 2018 using PubMed and OVID. We included comparative studies of TAVI patients with B-AV versus T-AV reporting at least one of postprocedural transcatheter valve regurgitation (TVR)/pacemaker implantation (PMI) incidence and early (30-day or in-hospital)/late (including early) mortality. For each study, crude (unadjusted) data regarding TVR/PMI incidence and early/late mortality in both the B-AV and T-AV groups were used to generate risk ratios (RRs). Study-specific estimates were combined in the random-effects model. Using meta-regression, we assessed potential confounders identified in preliminary meta-analysis. RESULTS: We identified 12 eligible studies including a total of 1045 B-AV and 4069 T-AV patients. Pooled analysis demonstrated an association of B-AV with a statistically significant increase in TVR incidence (RR, 1.42; p=0.006) but no statistically significant difference in PMI incidence (p=0.54) and 30-day (p=0.11)/midterm (1-year to 2-year) mortality (p=0.99) between patients with B-AV and those with T-AV. All meta-regression coefficients of 6 identified potential confounders (age, mean aortic valve gradient, aortic valve area, left ventricular ejection fraction, aortic calcification, and B-AV types) for the outcomes (TVR/PMI incidence and early/late mortality) were statistically non-significant. CONCLUSIONS: Postprocedural PMI incidence and 30-day/midterm (1-year to 2-year) mortality after TAVI may be similar between patients with B-AV and those with T-AV despite the significant association of B-AV with increased postprocedural TVR incidence.